ALNY - アルナイラム・ファ―マシュ―ティカルズ (Alnylam Pharmaceuticals Inc.) アルナイラム・ファ―マシュ―ティカルズ



symbol ALNY
会社名 Alnylam Pharmaceuticals Inc (アルナイラム・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アルナイラム・ファーマシューティカルズ(Alnylam Pharmaceuticals Inc.)はリボ核酸干渉法(RNAi)に基づく治療薬を開発する生物医薬品会社である。同社の「Alnylam 5x15」は遺伝的疾患の治療向けに、リボ核酸干渉法を用いた新規治療薬の開発及び商品化に注力する。同社の臨床または前臨床開発段階の中核プログラムには、トランスサイレチン媒介性アミロイドーシス(ATTR)の治療向けの「ALN-TTR」、血友病の治療向けの「ALN-APC」、重度の高コレステロール血症の治療向けの「ALN-PCS」、不応性貧血の治療向けの「ALN-HPN」、並びにベータサラセミア及び鎌状赤血球貧血症を含む異常ヘモグロビン症の治療向けの「ALN-TMP」が含まれる。パートナーベースのプログラムとしては、同社は呼吸器合胞体ウイルス(RSV)感染症の治療向けの「ALN-RSV01」、肝癌の治療向けの「ALN-VSP」、並びにハンチントン病(HD)の治療向けの「ALN-HTT」を含む臨床または前臨床開発段階のプログラムを3つ有する。   アルナイラム・ファ―マシュ―ティカルズは米国のバイオテクノロジ―企業。2002年の創業以来、一貫してRNAi(各種疾患の原因となるタンパク質を作り出す遺伝子に直接・選択的に作用する特徴を有する)技術を基盤とした医薬品研究開発を行い、RNAi医薬の研究・開発に必要な多くの特許、技術を保持する。本社はマサチュ―セッツ州ケンブリッジ。   Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
本社所在地 300 Third Street Cambridge MA 02142 USA
代表者氏名 Michael W. Bonney マイケル・W・ボニー
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-551-8200
設立年月日 37742
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 749人
EBITDA EBITDA(百万ドル) -600.14400
終値(lastsale) 83.21
時価総額(marketcap) 8376427179.52
時価総額 時価総額(百万ドル) 8222.408
売上高 売上高(百万ドル) 106.82600
企業価値(EV) 企業価値(EV)(百万ドル) 6804.742
当期純利益 当期純利益(百万ドル) -570.73800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Alnylam Pharmaceuticals Inc. revenues increased 48% to $51.8M. Net loss before extraordinary items increased 35% to $305.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $40.5M to $87.2M (expense).



   Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary  2022/09/15 22:47:02 Benzinga
Pfizer (NYSE: PFE ) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7 to $46.29 on day volume of 15.14 million shares, closed regular trading session at $45.94. Alnylam (NASDAQ: ALNY) and Regeneron (NASDAQ: REGN) announced preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). Alnylam shares traded in a range of $202.6 to $210.86 on day volume of 771.5 thousand shares, closed regular trading session at $208.48. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kymera Therapeutics ’ (NASDAQ: KYMR ) product candidate KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL).
   Can you still get a good price for Alnylam Pharmaceuticals Inc. (ALNY) Shares at this point?  2022/09/15 14:48:00 US Post News
A share of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) closed at $208.28 per share on Wednesday, up from $206.59 day before. While Alnylam Pharmaceuticals Inc. has overperformed by 0.82%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALNY rose by 10.80%, with highs and lows ranging from $236.80 […]
   Alnylam/Regeneron say early-stage data back Phase 2 trial for NASH drug (NASDAQ:REGN)  2022/09/15 11:29:28 Seeking Alpha
Alnylam (ALNY) and Regeneron (REGN) announced Thursday that early Phase 1 data for ALN-HSD, an experimental therapy for liver disease nonalcoholic steatohepatitis ((NASH)), supported…
   Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers  2022/09/15 11:00:00 Business Wire
CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). After single-dose evaluation in healthy adult volunteers (Part A), multiple doses of ALN-HSD are being studied in adult patients with NASH
   Alnylam prices $900M debt offering (NASDAQ:ALNY)  2022/09/13 11:53:18 Seeking Alpha
Alnylam (ALNY) has priced its previously announced private offering of $900M principal amount of 1.00% convertible senior notes due 2027.The initial purchasers are granted an option…
   KB Financial Partners LLC Takes $178,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)  2021/11/08 15:22:41 Dakota Financial News
KB Financial Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,050 shares of the biopharmaceutical companys stock, valued at approximately $178,000. Several other institutional investors have also []
   Beam Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to its Board of Directors  2021/11/08 11:00:00 Intrado Digital Media
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Maraganore, Ph.D., founding chief executive officer and director of Alnylam Pharmaceuticals, has joined the companys board of directors.
   Canada Pension Plan Investment Board Trims Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)  2021/11/07 11:50:49 Dakota Financial News
Canada Pension Plan Investment Board lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 66.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 39,690 shares of the biopharmaceutical companys stock after selling 78,667 shares during the quarter. Canada Pension []
   Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) Is Up 35.47% From Its 52-Week Low; YTD, It Is Up 44.07% What To Do Now  2021/11/06 17:00:00 Marketing Sentinel
During the last session, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)s traded shares were 0.71 million, with the beta value of the company hitting 0.97. At the end of the trading day, the stocks price was $187.25, reflecting an intraday gain of 0.92% or $1.7. The 52-week high for the ALNY share is $212.00, that puts it down Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) Is Up 35.47% From Its 52-Week Low; YTD, It Is Up 44.07% What To Do Now Read More »
   Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1  2021/11/05 17:30:00 Wallstreet:Online
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) the gene encoding glycolate oxidase (GO) that is being investigated for the treatment of patients of all ages with advanced
   Allstate Closes Sale of New York Life and Annuity Businesses  2021/10/01 15:41:00 Business Wire
NORTHBROOK, Ill.--(BUSINESS WIRE)--The Allstate Corporation (NYSE: ALL) today announced that it has obtained all required regulatory approvals and closed the sale of Allstate Life Insurance Company of New York (ALNY) to Wilton Re for approximately $400 million. Closing on the sale of ALNY is a significant step in Allstates strategy of increasing personal property-liability market share and expanding protection services, while deploying capital out of the life and annuity businesses, said Mar
   Gene Delivery System Technology Drug Market 2021 Growing Demand, Size and Business Outlook - Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals  2021/09/30 12:14:45 OpenPR
The report begins with the overview of the Gene Delivery System Technology Drug Market and offers throughout development. It presents a comprehensive analysis of all the regional and major player segments that gives closer insights upon present market conditions and
   Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference  2021/09/28 20:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:30 pm ET. A live audio webcast of the presentation will be available on the Investors section of the Companys website at A replay will be available on the Alnylam website within 48 hours after t
   Novartis AG Consensus Indicates Potential 26.6% Upside  2021/09/24 09:42:37 DirectorsTalk
Novartis AG with ticker code (NVS) have now 5 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 108 and 100 with the average target price sitting at 104.8. With the stocks previous close at 82.8 this is indicating there is a potential upside of 26.6%. The 50 day moving average now sits at 89.97 while the 200 day moving average is 89.3. The market capitalisation for the company is $187,269m. Find out more information at: /> [stock_market_widget type="chart" symbol="NVS" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.
   Alnylam Pharma Submits MAA To EMA For Vutrisiran For Hereditary ATTR Amyloidosis With Polyneuropathy  2021/09/13 11:29:59 Business Insider Markets
(RTTNews) - RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アルナイラム・ファ―マシュ―ティカルズ ALNY Alnylam Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)